Acute Promyelocytic Leukemia (APML)

Dear Colleagues, 

Acute promyelocytic leukemia (APL) has become the poster child of success in hematological malignancies. Contemplating survival data from clinical trials, one may be left thinking that there are no mysteries or challenges left when it comes to the molecular and cellular biology of APL or to the management of this disease. Nevertheless, now more than ever, we should reflect on lessons learned from APL and imagine a future in which similar progress can be seen in all types of acute leukemia and cancer in general. More so, a close look at real life outcomes in this disease shows a sobering reality in which patients with APL suffer higher morbidity and mortality compared to data reported from clinical trials. Thus, a critical examination of how we diagnose and manage patients with APL on a day-to-day basis is necessary to improve the quality of life and overall outcomes for all patients with this disease, not only those treated in large academic centers from developed countries.

This Special Issue of Cancers aims to encompass the current clinical, epidemiological, and biological knowledge of APL and serve as a reference resource for academicians, clinicians, and molecular biologist alike.

Dr. Gabriel Ghiaur
Dr. Andrei Coliță
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.